ÖÐÎÄÃû³Æ£º CD22¿¹Ô£¨ÖØ×éµ°°×£©
Ó¢ÎÄÃû³Æ£º CD22 Antigen (Recombinant Protein)
±ð Ãû£º SIGLEC2; SIGLEC-2
´¢ ´æ£º Àä¶³£¨-20¡æ£©
Ïà¹ØÀà±ð£º ¿¹Ô
¸Å Êö£º
|
Fusion protein corresponding to a region derived from C terminal 250 amino acids of human CD22 |
¼¼Êõ¹æ¸ñ£º
|
Full name: |
CD22 molecule |
|
Synonyms: |
SIGLEC2; SIGLEC-2 |
|
Swissprot: |
P20273 |
|
Gene Accession: |
BC109306 |
|
Purity: |
>85%, as determined by Coomassie blue stained SDS-PAGE |
|
Expression system: |
Escherichia coli |
|
Tags: |
His tag C-Terminus, GST tag N-Terminus |
|
Background: |
The B lymphocyte specific CD22 antigen, also designated B-lymphocyte cell adhesion molecule (BLCAM), sialic acid-binding Ig-like lectin 2 (Siglec-2) and Leu-14, is a type I integral membrane glycoprotein, structurally similar to other cell adhesion molecules (CAMs), which acts as a regulator of B cell signaling. CD22 is expressed as both a cytoplasmic and membrane protein during discrete stages of B cell lymphocyte differentiation. The cytoplasmic form of CD22, expressed early in B cell development, is a useful marker for acute lymphocytic leukemia. The membrane form of CD22 is expressed in mature B cells prior to their differentiation into plasma cells. |
¹ºÎï³µ
°ïÖú
021-54845833/15800441009
